Pfenex Inc. (PFNX)
Symbol Info
Listed Symbol PFNX
Name Pfenex Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $14,857,000
Latest Fiscal EPS $-1.42
Price Info
21 Day Moving Average $7.9643
21 Day EMA $8.258640
50 Day Moving Average $6.9680
50 Day EMA $7.415870
200 Day EMA $6.123970
200 Day Moving Average 5.648850
52 Week High $10.20
52 Week Low $3.13
52 Week Change $111.648410
Alpha 0.009273
Beta 2.3295
Standard Deviation 0.237510
R2 0.114303
Periods 60
Share Information
10 Day Average Volume 248,193
20 Day Average Volume 191,717
30 Day Average Volume 167,118
50 Day Average Volume 161,646
Outstanding Shares 31,597,592
Float Shares 30,814,200
Percent Float 97.52%
Short Interest 486,236
Short Percent Float 1.50%
Short Interest Ratio 3.59
Short Date 2019-08-30
Holders
Institutions 170
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 1,551,900
Institute Holdings Percent -
Institute Sold Previous 3 Months 1,814,415
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 783,392
Price Change
7 Day Price Change $0.6199999
7 Day Percent Change 6.88%
21 Day Price Change $2.4200000
21 Day Percent Change 33.56%
30 Day Price Change $2.6800003
30 Day Percent Change 38.56%
Month To Date Price Change $2.2800
Month To Date Percent 31.02%
90 Day Price Change $2.680000
90 Day Percent Change 38.56%
Quarter To Date $2.890000
Quarter To Date Percent 42.88%
180 Day Price Change $4.690000
180 Day Percent Change 94.94%
200 Day Price Change $4.470000
200 Day Percent Change 86.63%
Year To Date $6.440000
Year To Date Percent 201.88%
Profile
Description Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.
Details
Issue Type CS
Market Cap $307,444,570
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 31,597,592
CEO Evert B. Schimmelpennink
Employees 78
Last Audit UQ
Classification
CIK 0001478121
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 10790 Roselle Street
San Diego, CA 92121
Website http://www.pfenex.com
Facisimile +1 858 352-4602
Telephone +1 858 352-4400
Email sknudson@pfenex.com
Key Ratios
Profitability
EBIT Margin -145
EBITDA Margin -136.3
Pre-Tax Profit Margin -145.9
Profit Margin Cont -
Gross Margin 73.80
Profit Margin TOT -
Income Statements
Revenue $20,094,000
Revenue Per Share $0.6359
Revenue 3 Years $-12.72
Revenue 5 Years $14.27
Valuation Measures
PE Ratio -
Enterprise Value $187,838,542
Price To Sales 15.143068
Price To Free Cash -5.9
PE High Last 5 Years -
Price To Book 4.4
Price To Cash Flow 7.5
PE Low Last 5 Years -
Price To Tangible Book 5.4
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 4.8
Leverage Ratio 1.3
Quick Ratio 4.6
Long Term Debt To Capital -
Assets
Receivables Turnover 7.7
Invoice Turnover -
Assets Turnover 0.30
Management Effectiveness
Return Assets -35.34
Return On Equity -45.34
Return On Capital -44.3
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
AMEX
PFNX
Pfenex
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.